Global Plaque Psoriasis Treatment Market
Global Plaque Psoriasis Treatment Market

Plaque Psoriasis Treatment Comprehensive Study by Type (Topical Therapy, Phototherapy, Systemic Agents, Biologic Therapies), Application (Hospitals, Clinics, Others), Drug Class (TNF-α Inhibitors, IL-12/23 Inhibitor, IL-17 Inhibitors) Players and Region - Global Market Outlook to 2026

Plaque Psoriasis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 222 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Plaque Psoriasis Treatment Market?

With the growing number of pipeline psoriasis molecules and biologics being released, the demand for plaque psoriasis treatment is expected to soar. Plaque psoriasis is an autoimmune inflammatory disorder that causes excessive skin cell production. Inflamed, elevated, scaly red plaques and lesions characterize the skin. Environmental factors such as sun exposure, smoking, HIV infection, and alcoholism may influence the severity and frequency of psoriasis. In younger psoriasis patients, psoriasis raises the risk of myocardial infarction by three times.

The market study is being classified by Type (Topical Therapy, Phototherapy, Systemic Agents and Biologic Therapies), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.

Allergan (United States), Johnson and Johnson (United States), Amgen (United States), Abbvie (United States), Eli Lilly (United States), Dermira (United States), Novartis (Switzerland), Galectin Therapeutics (United States), Cellceutix (United States), Biogen (United States) and Bayer (Germany) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Plaque Psoriasis Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Plaque Psoriasis Treatment market by Type, Application and Region.

On the basis of geography, the market of Plaque Psoriasis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Number of Pipeline Psoriasis Molecule and the Number of Biologics being Launched

Market Trend
  • Increasing Approval of Pipeline Drugs and Supplemental Biologics

Restraints
  • High Cost of Drug Development

Opportunities
  • Increased Research and Development Funding
  • Growth in the Healthcare Industry Worldwide

Challenges
  • Lack of Awareness


In Oct 2020, LEO Pharma Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment
In Aug 2020, Novartis announced the European Commission (EC) has granted the approval for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The recommended dose for children up to 50 kg is 75 mg (without a lower weight restriction), and 150 mg for children 50 kg and over (150 mg as a starting dose, which may be increased to 300 mg, if needed).

Key Target Audience
Plaque Psoriasis Treatment Providers, Potential Investors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Topical Therapy
  • Phototherapy
  • Systemic Agents
  • Biologic Therapies
By Application
  • Hospitals
  • Clinics
  • Others
By Drug Class
  • TNF-α Inhibitors
  • IL-12/23 Inhibitor
  • IL-17 Inhibitors

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Pipeline Psoriasis Molecule and the Number of Biologics being Launched
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness
    • 3.4. Market Trends
      • 3.4.1. Increasing Approval of Pipeline Drugs and Supplemental Biologics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Plaque Psoriasis Treatment, by Type, Application, Drug Class and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Plaque Psoriasis Treatment (Value)
      • 5.2.1. Global Plaque Psoriasis Treatment by: Type (Value)
        • 5.2.1.1. Topical Therapy
        • 5.2.1.2. Phototherapy
        • 5.2.1.3. Systemic Agents
        • 5.2.1.4. Biologic Therapies
      • 5.2.2. Global Plaque Psoriasis Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Plaque Psoriasis Treatment by: Drug Class (Value)
        • 5.2.3.1. TNF-α Inhibitors
        • 5.2.3.2. IL-12/23 Inhibitor
        • 5.2.3.3. IL-17 Inhibitors
      • 5.2.4. Global Plaque Psoriasis Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Plaque Psoriasis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson and Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbvie (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dermira (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Galectin Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cellceutix (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biogen (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bayer (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Plaque Psoriasis Treatment Sale, by Type, Application, Drug Class and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Plaque Psoriasis Treatment (Value)
      • 7.2.1. Global Plaque Psoriasis Treatment by: Type (Value)
        • 7.2.1.1. Topical Therapy
        • 7.2.1.2. Phototherapy
        • 7.2.1.3. Systemic Agents
        • 7.2.1.4. Biologic Therapies
      • 7.2.2. Global Plaque Psoriasis Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Plaque Psoriasis Treatment by: Drug Class (Value)
        • 7.2.3.1. TNF-α Inhibitors
        • 7.2.3.2. IL-12/23 Inhibitor
        • 7.2.3.3. IL-17 Inhibitors
      • 7.2.4. Global Plaque Psoriasis Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Plaque Psoriasis Treatment: by Type(USD Million)
  • Table 2. Plaque Psoriasis Treatment Topical Therapy , by Region USD Million (2015-2020)
  • Table 3. Plaque Psoriasis Treatment Phototherapy , by Region USD Million (2015-2020)
  • Table 4. Plaque Psoriasis Treatment Systemic Agents , by Region USD Million (2015-2020)
  • Table 5. Plaque Psoriasis Treatment Biologic Therapies , by Region USD Million (2015-2020)
  • Table 6. Plaque Psoriasis Treatment: by Application(USD Million)
  • Table 7. Plaque Psoriasis Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 8. Plaque Psoriasis Treatment Clinics , by Region USD Million (2015-2020)
  • Table 9. Plaque Psoriasis Treatment Others , by Region USD Million (2015-2020)
  • Table 10. Plaque Psoriasis Treatment: by Drug Class(USD Million)
  • Table 11. Plaque Psoriasis Treatment TNF-α Inhibitors , by Region USD Million (2015-2020)
  • Table 12. Plaque Psoriasis Treatment IL-12/23 Inhibitor , by Region USD Million (2015-2020)
  • Table 13. Plaque Psoriasis Treatment IL-17 Inhibitors , by Region USD Million (2015-2020)
  • Table 14. South America Plaque Psoriasis Treatment, by Country USD Million (2015-2020)
  • Table 15. South America Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 16. South America Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 17. South America Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 18. Brazil Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 19. Brazil Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 20. Brazil Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 21. Argentina Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 22. Argentina Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 23. Argentina Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 24. Rest of South America Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 27. Asia Pacific Plaque Psoriasis Treatment, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 31. China Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 32. China Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 33. China Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 34. Japan Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 35. Japan Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 36. Japan Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 37. India Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 38. India Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 39. India Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 40. South Korea Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 41. South Korea Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 42. South Korea Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 43. Taiwan Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 44. Taiwan Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 45. Taiwan Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 46. Australia Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 47. Australia Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 48. Australia Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 52. Europe Plaque Psoriasis Treatment, by Country USD Million (2015-2020)
  • Table 53. Europe Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 54. Europe Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 55. Europe Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 56. Germany Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 57. Germany Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 58. Germany Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 59. France Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 60. France Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 61. France Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 62. Italy Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 63. Italy Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 64. Italy Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 65. United Kingdom Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 68. Netherlands Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 69. Netherlands Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 70. Netherlands Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 71. Rest of Europe Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 74. MEA Plaque Psoriasis Treatment, by Country USD Million (2015-2020)
  • Table 75. MEA Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 76. MEA Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 77. MEA Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 78. Middle East Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 79. Middle East Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 80. Middle East Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 81. Africa Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 82. Africa Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 83. Africa Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 84. North America Plaque Psoriasis Treatment, by Country USD Million (2015-2020)
  • Table 85. North America Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 86. North America Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 87. North America Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 88. United States Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 89. United States Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 90. United States Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 91. Canada Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 92. Canada Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 93. Canada Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 94. Mexico Plaque Psoriasis Treatment, by Type USD Million (2015-2020)
  • Table 95. Mexico Plaque Psoriasis Treatment, by Application USD Million (2015-2020)
  • Table 96. Mexico Plaque Psoriasis Treatment, by Drug Class USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Plaque Psoriasis Treatment: by Type(USD Million)
  • Table 109. Plaque Psoriasis Treatment Topical Therapy , by Region USD Million (2021-2026)
  • Table 110. Plaque Psoriasis Treatment Phototherapy , by Region USD Million (2021-2026)
  • Table 111. Plaque Psoriasis Treatment Systemic Agents , by Region USD Million (2021-2026)
  • Table 112. Plaque Psoriasis Treatment Biologic Therapies , by Region USD Million (2021-2026)
  • Table 113. Plaque Psoriasis Treatment: by Application(USD Million)
  • Table 114. Plaque Psoriasis Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 115. Plaque Psoriasis Treatment Clinics , by Region USD Million (2021-2026)
  • Table 116. Plaque Psoriasis Treatment Others , by Region USD Million (2021-2026)
  • Table 117. Plaque Psoriasis Treatment: by Drug Class(USD Million)
  • Table 118. Plaque Psoriasis Treatment TNF-α Inhibitors , by Region USD Million (2021-2026)
  • Table 119. Plaque Psoriasis Treatment IL-12/23 Inhibitor , by Region USD Million (2021-2026)
  • Table 120. Plaque Psoriasis Treatment IL-17 Inhibitors , by Region USD Million (2021-2026)
  • Table 121. South America Plaque Psoriasis Treatment, by Country USD Million (2021-2026)
  • Table 122. South America Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 123. South America Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 124. South America Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 125. Brazil Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 126. Brazil Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 127. Brazil Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 128. Argentina Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 129. Argentina Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 130. Argentina Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 131. Rest of South America Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 132. Rest of South America Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 133. Rest of South America Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 134. Asia Pacific Plaque Psoriasis Treatment, by Country USD Million (2021-2026)
  • Table 135. Asia Pacific Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 136. Asia Pacific Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 137. Asia Pacific Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 138. China Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 139. China Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 140. China Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 141. Japan Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 142. Japan Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 143. Japan Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 144. India Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 145. India Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 146. India Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 147. South Korea Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 148. South Korea Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 149. South Korea Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 150. Taiwan Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 151. Taiwan Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 152. Taiwan Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 153. Australia Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 154. Australia Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 155. Australia Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 159. Europe Plaque Psoriasis Treatment, by Country USD Million (2021-2026)
  • Table 160. Europe Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 161. Europe Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 162. Europe Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 163. Germany Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 164. Germany Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 165. Germany Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 166. France Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 167. France Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 168. France Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 169. Italy Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 170. Italy Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 171. Italy Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 172. United Kingdom Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 173. United Kingdom Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 174. United Kingdom Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 175. Netherlands Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 176. Netherlands Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 177. Netherlands Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 178. Rest of Europe Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 179. Rest of Europe Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 180. Rest of Europe Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 181. MEA Plaque Psoriasis Treatment, by Country USD Million (2021-2026)
  • Table 182. MEA Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 183. MEA Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 184. MEA Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 185. Middle East Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 186. Middle East Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 187. Middle East Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 188. Africa Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 189. Africa Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 190. Africa Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 191. North America Plaque Psoriasis Treatment, by Country USD Million (2021-2026)
  • Table 192. North America Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 193. North America Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 194. North America Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 195. United States Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 196. United States Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 197. United States Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 198. Canada Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 199. Canada Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 200. Canada Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 201. Mexico Plaque Psoriasis Treatment, by Type USD Million (2021-2026)
  • Table 202. Mexico Plaque Psoriasis Treatment, by Application USD Million (2021-2026)
  • Table 203. Mexico Plaque Psoriasis Treatment, by Drug Class USD Million (2021-2026)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Plaque Psoriasis Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Plaque Psoriasis Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Plaque Psoriasis Treatment: by Drug Class USD Million (2015-2020)
  • Figure 7. South America Plaque Psoriasis Treatment Share (%), by Country
  • Figure 8. Asia Pacific Plaque Psoriasis Treatment Share (%), by Country
  • Figure 9. Europe Plaque Psoriasis Treatment Share (%), by Country
  • Figure 10. MEA Plaque Psoriasis Treatment Share (%), by Country
  • Figure 11. North America Plaque Psoriasis Treatment Share (%), by Country
  • Figure 12. Global Plaque Psoriasis Treatment share by Players 2020 (%)
  • Figure 13. Global Plaque Psoriasis Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Plaque Psoriasis Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergan (United States) Revenue, Net Income and Gross profit
  • Figure 17. Allergan (United States) Revenue: by Geography 2020
  • Figure 18. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 19. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 20. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 21. Amgen (United States) Revenue: by Geography 2020
  • Figure 22. Abbvie (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbvie (United States) Revenue: by Geography 2020
  • Figure 24. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 25. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 26. Dermira (United States) Revenue, Net Income and Gross profit
  • Figure 27. Dermira (United States) Revenue: by Geography 2020
  • Figure 28. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 30. Galectin Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 31. Galectin Therapeutics (United States) Revenue: by Geography 2020
  • Figure 32. Cellceutix (United States) Revenue, Net Income and Gross profit
  • Figure 33. Cellceutix (United States) Revenue: by Geography 2020
  • Figure 34. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 35. Biogen (United States) Revenue: by Geography 2020
  • Figure 36. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Bayer (Germany) Revenue: by Geography 2020
  • Figure 38. Global Plaque Psoriasis Treatment: by Type USD Million (2021-2026)
  • Figure 39. Global Plaque Psoriasis Treatment: by Application USD Million (2021-2026)
  • Figure 40. Global Plaque Psoriasis Treatment: by Drug Class USD Million (2021-2026)
  • Figure 41. South America Plaque Psoriasis Treatment Share (%), by Country
  • Figure 42. Asia Pacific Plaque Psoriasis Treatment Share (%), by Country
  • Figure 43. Europe Plaque Psoriasis Treatment Share (%), by Country
  • Figure 44. MEA Plaque Psoriasis Treatment Share (%), by Country
  • Figure 45. North America Plaque Psoriasis Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Allergan (United States)
  • Johnson and Johnson (United States)
  • Amgen (United States)
  • Abbvie (United States)
  • Eli Lilly (United States)
  • Dermira (United States)
  • Novartis (Switzerland)
  • Galectin Therapeutics (United States)
  • Cellceutix (United States)
  • Biogen (United States)
  • Bayer (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation